Andrew Collett
Research Interests
Andrew Collett has a total of 89 co-authors. Here are the top co-authors by number of shared publications:
Geoff Warhurst
University of Manchester, Gut Barrier Group, Clinical Sciences Building, Hope Hospital, Salford M6 8HD, UK
3 shared publicationsJohn Ayrton
GlaxoWellcome
3 shared publicationsMalcolm Rowland
University of Manchester
3 shared publications- Stuart M. Wilson
Centre for Cardiovascular and Lung Biology, Division of Medical Sciences, College of Medicine, Dentistry and Nursing, University of Dundee, Dundee, UK
3 shared publications - Andrew P. Laws
Department of Chemical Sciences, University of Huddersfield, Queensgate, Huddersfield, HD1 3DH, United Kingdom
2 shared publications D L Baines
11Lung Membrane Transport Group, Tayside Institute of Child Health, Ninewells Hospital and Medical School, University of Dundee, Dundee DD1 9SY
2 shared publications
Latest Publications
- Open Access
Evidence for the Modulation of the Immune Response in Peripheral Blood Mononuclear Cells after Stimulation with a High Molecular Weight β-glucan Isolated from Lactobacillus fermentum Lf2
Lactobacillus fermentum Lf 2 produces large amounts of exopolysaccharides under optimized conditions (∼2 g/L, EPS) which have been shown to possess immunomodulatory activity. In this study, the crude EPS was fractionated to give a high molecular weight (HMw) homoglycan and a mixture of medium molecular weight heteroglycans. The HMw EPS was isolated and identified as a β-glucan. Peripheral blood mononuclear cells (PBMC) were pre-treated with purified polysaccharide to determine if the HMw β-glucan is responsible for the immunomodulatory activity. Cells were also stimulated with either lipopolysaccharide (LPS) or phytohemagglutinin (PHA) and their effects, both with and without β-glucan pre-treatment, compared. Exposure of the cells to β-glucan increased their metabolic activity and whilst a small but statistically significant drop in CD14 expression was observed at Day 1, the levels were significantly elevated at Day 2. High levels of CD14 expression were observed in cells initially exposed to the β-glucan and subsequently stimulated with either LPS or PHA. In contrast, reduced levels of TLR-2 expression were observed for cells initially exposed to the β-glucan and subsequently stimulated with LPS. TNF-α levels were elevated in β-glucan treated cells (Day1) with the levels dropping back once the β-glucan had been removed (Day 2). The stimulants LPS and PHA both induced significant rises in TNF-α levels, however, this induction was completely (LPS) or partially blocked (PHA) in β-glucan pre-treated cells. The results indicate a role for the bacterial β-glucan in modulating the immune response following exposure to agonists such as bacterial LPS.
Open AccessEvidence for the Modulation of the Immune Response in Peripheral Blood Mononuclear Cells after Stimulation with a High Molecular Weight β-glucan Isolated from Lactobacillus fermentum Lf2
Lactobacillus fermentum Lf 2 produces large amounts of exopolysaccharides under optimized conditions (∼2 g/L, EPS) which have been shown to possess immunomodulatory activity. In this study, the crude EPS was fractionated to give a high molecular weight (HMw) homoglycan and a mixture of medium molecular weight heteroglycans. The HMw EPS was isolated and identified as a β-glucan. Peripheral blood mononuclear cells (PBMC) were pre-treated with purified polysaccharide to determine if the HMw β-glucan is responsible for the immunomodulatory activity. Cells were also stimulated with either lipopolysaccharide (LPS) or phytohemagglutinin (PHA) and their effects, both with and without β-glucan pre-treatment, compared. Exposure of the cells to β-glucan increased their metabolic activity and whilst a small but statistically significant drop in CD14 expression was observed at Day 1, the levels were significantly elevated at Day 2. High levels of CD14 expression were observed in cells initially exposed to the β-glucan and subsequently stimulated with either LPS or PHA. In contrast, reduced levels of TLR-2 expression were observed for cells initially exposed to the β-glucan and subsequently stimulated with LPS. TNF-α levels were elevated in β-glucan treated cells (Day1) with the levels dropping back once the β-glucan had been removed (Day 2). The stimulants LPS and PHA both induced significant rises in TNF-α levels, however, this induction was completely (LPS) or partially blocked (PHA) in β-glucan pre-treated cells. The results indicate a role for the bacterial β-glucan in modulating the immune response following exposure to agonists such as bacterial LPS.
- 1 December 2014
- Published by Elsevier in Toxicology in Vitro
- Vol. 28 (8) , 1366-1376
Use of in vitro human keratinocyte models to study the effect of cooling on chemotherapy drug-induced cytotoxicity
- 1 December 2014
- Published by Elsevier in Toxicology in Vitro
- Vol. 28 (8) , 1366-1376
Use of in vitro human keratinocyte models to study the effect of cooling on chemotherapy drug-induced cytotoxicity
- Open Access
- 1 August 2013
- Published by Microbiology Society in Microbiology
- Vol. 159 (Pt_8) , 1535-1544
Exploring the immunomodulatory potential of microbial-associated molecular patterns derived from the enteric bacterial microbiota
The human intestinal lumen represents one of the most densely populated microbial niches in the biological world and, as a result, the intestinal innate immune system exists in a constant state of stimulation. A key component in the innate defence system is the intestinal epithelial layer, which acts not only as a physical barrier, but also as an immune sensor. The expression of pattern recognition receptors, such as Toll-like receptors, in epithelial cells allows innate recognition of a wide range of highly conserved bacterial moieties, termed microbial-associated molecular patterns (MAMPs), from both pathogenic and non-pathogenic bacteria. To date, studies of epithelial immunity have largely concentrated on inflammatory pathogenic antigens; however, this review discusses the major types of MAMPs likely to be produced by the enteric bacterial microbiota and, using data from in vitro studies, animal model systems and clinical observations, speculates on their immunomodulatory potential.
- 1 August 2013
- Published by Microbiology Society in Microbiology
- Vol. 159 (Pt_8) , 1535-1544
Open AccessExploring the immunomodulatory potential of microbial-associated molecular patterns derived from the enteric bacterial microbiota
The human intestinal lumen represents one of the most densely populated microbial niches in the biological world and, as a result, the intestinal innate immune system exists in a constant state of stimulation. A key component in the innate defence system is the intestinal epithelial layer, which acts not only as a physical barrier, but also as an immune sensor. The expression of pattern recognition receptors, such as Toll-like receptors, in epithelial cells allows innate recognition of a wide range of highly conserved bacterial moieties, termed microbial-associated molecular patterns (MAMPs), from both pathogenic and non-pathogenic bacteria. To date, studies of epithelial immunity have largely concentrated on inflammatory pathogenic antigens; however, this review discusses the major types of MAMPs likely to be produced by the enteric bacterial microbiota and, using data from in vitro studies, animal model systems and clinical observations, speculates on their immunomodulatory potential.
- 14 September 2009
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 423 (1) , 119-128
Potentiation of flagellin responses in gut epithelial cells by interferon-γ is associated with STAT-independent regulation of MyD88 expression
Flagellin acting via TLR5 (Toll-like receptor 5) is a key regulator of the host response to the gilt microbial flora in both health and disease. The present study has investigated regulation of flagellin-TLR5 signalling in human colonocytes (HT29-19A) by IFN gamma (interferon-gamma), a cytokine released early in the inflammatory process which has multiple effects oil gut epithelial function that may facilitate abnormal responses to enteric bacteria. Flagellin induced a dose-dependent secretion of chemokines CXCL8 and CCL2 in the human colonocyte line, HT29-19A. Exposure to IFN gamma did not induce chemokine secretion, but markedly potentiated responses to flagellin, increasing CXL8 gene expression and protein secretion by approx. 4-fold. Potentiation by IFN gamma was independent of changes in TLR5 and was associated with a rapid, sustained increase in expression of the downstream adaptor molecule MyD88 (myeloid differentiation factor 88). Knockdown of MyD88 expression using siRNA (small interfering RNA) abolished flagellin-dependent CXCL8 secretion and the potentiating effect of IFN gamma. Exposure of non-transformed mouse and human colonocytes to IFN gamma also increased MyD88 expression. STAT (signal transducer and activator of transcription) I knockdown and use of the broad-spectrum JAK (Janus kinase)STAT inhibitor AG490 had no effect on IFN gamma-mediated up-regulation of MyD88. The findings of the present study suggest that IFN gamma sensitizes colonic epithelial cells to bacterial flagellin via a largely STAT-independent up-regulation of MyD88 expression leading to increased secretion of immunomodulatory factors. These results indicate that epithelial responses to flagellin are potentiated by IFN gamma, most likely mediated by increased MyD88 expression. The present Study adds to our understanding of the spectrum of effects of this cytokine on gut epithelium that may contribute to bacterial-driven inflammation in the gut.
- 14 September 2009
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 423 (1) , 119-128
Potentiation of flagellin responses in gut epithelial cells by interferon-γ is associated with STAT-independent regulation of MyD88 expression
Flagellin acting via TLR5 (Toll-like receptor 5) is a key regulator of the host response to the gilt microbial flora in both health and disease. The present study has investigated regulation of flagellin-TLR5 signalling in human colonocytes (HT29-19A) by IFN gamma (interferon-gamma), a cytokine released early in the inflammatory process which has multiple effects oil gut epithelial function that may facilitate abnormal responses to enteric bacteria. Flagellin induced a dose-dependent secretion of chemokines CXCL8 and CCL2 in the human colonocyte line, HT29-19A. Exposure to IFN gamma did not induce chemokine secretion, but markedly potentiated responses to flagellin, increasing CXL8 gene expression and protein secretion by approx. 4-fold. Potentiation by IFN gamma was independent of changes in TLR5 and was associated with a rapid, sustained increase in expression of the downstream adaptor molecule MyD88 (myeloid differentiation factor 88). Knockdown of MyD88 expression using siRNA (small interfering RNA) abolished flagellin-dependent CXCL8 secretion and the potentiating effect of IFN gamma. Exposure of non-transformed mouse and human colonocytes to IFN gamma also increased MyD88 expression. STAT (signal transducer and activator of transcription) I knockdown and use of the broad-spectrum JAK (Janus kinase)STAT inhibitor AG490 had no effect on IFN gamma-mediated up-regulation of MyD88. The findings of the present study suggest that IFN gamma sensitizes colonic epithelial cells to bacterial flagellin via a largely STAT-independent up-regulation of MyD88 expression leading to increased secretion of immunomodulatory factors. These results indicate that epithelial responses to flagellin are potentiated by IFN gamma, most likely mediated by increased MyD88 expression. The present Study adds to our understanding of the spectrum of effects of this cytokine on gut epithelium that may contribute to bacterial-driven inflammation in the gut.
- Open Access
- 1 May 2008
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 14 (5) , 620-631
Early molecular and functional changes in colonic epithelium that precede increased gut permeability during colitis development in mdr1a(−/−) mice
Background. The early molecular changes preceding the onset of mucosal inflammation in colitis and their temporal relationship with gut permeability rem
- 1 May 2008
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 14 (5) , 620-631
Open AccessEarly molecular and functional changes in colonic epithelium that precede increased gut permeability during colitis development in mdr1a(−/−) mice
Background. The early molecular changes preceding the onset of mucosal inflammation in colitis and their temporal relationship with gut permeability rem
- 1 January 2008
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 36 (1) , 87-94
Investigation of Regional Mechanisms Responsible for Poor Oral Absorption in Humans of a Modified Release Preparation of the α-Adrenoreceptor Antagonist, 4-Amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4 tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline (UK-338,003): The Rational Use of ex Vivo Intestine to Predict in Vivo Absorption
Modified release (MR) formulations are used to enhance the safety and compliance of existing drugs by improving their pharmacokinetics. Predicting the likely success of MR formulations is often difficult before clinical studies. A systematic in vitro approach using mouse and human tissues was adopted to rationalize the in vivo pharmacokinetics of 9- and 15-h MR formulations of an α-adrenoreceptor antagonist, 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4 tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline (UK-338,003). Immediate release UK-338,003 was well absorbed in humans consistent with moderate Caco-2 cell monolayer permeability. In contrast, 9- and 15-h modified release formulations showed marked reductions in Cmax (47.1 and 68.9%) and AUC0–72 (32.6 and 54.0%). Colonic intubation resulted in 81.3 and 73.8% reductions in Cmax and AUC0–72. Mechanistic studies in isolated mouse tissues showed that colonic UK-338,003 permeability (Papp < 0.5 × 10-6 cm/s) was at least 40 times lower than that for ileum with marked asymmetry. UK-338,003 was found to be a substrate for P-glycoprotein (PGP) with a weaker interaction for multidrug resistance-associated protein-type transporters in mouse intestine. PGP inhibition dramatically increased colonic UK-338,003 permeability to the levels observed in ileum. Low UK-338,003 apical to basolateral permeability was also observed in ex vivo human distal intestine, but both the asymmetry and increase in permeability after PGP inhibition were significantly lower. In conclusion, the poor absorption of MR UK-338,003 in humans can be explained by a combination of PGP-dependent efflux and low intrinsic permeability in the lower bowel. Regional permeability studies in ex vivo tissues used during drug development can highlight absorption problems in the distal bowel and assess the feasibility of developing successful MR formulations.
- 1 January 2008
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 36 (1) , 87-94
Investigation of Regional Mechanisms Responsible for Poor Oral Absorption in Humans of a Modified Release Preparation of the α-Adrenoreceptor Antagonist, 4-Amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4 tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline (UK-338,003): The Rational Use of ex Vivo Intestine to Predict in Vivo Absorption
Modified release (MR) formulations are used to enhance the safety and compliance of existing drugs by improving their pharmacokinetics. Predicting the likely success of MR formulations is often difficult before clinical studies. A systematic in vitro approach using mouse and human tissues was adopted to rationalize the in vivo pharmacokinetics of 9- and 15-h MR formulations of an α-adrenoreceptor antagonist, 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4 tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline (UK-338,003). Immediate release UK-338,003 was well absorbed in humans consistent with moderate Caco-2 cell monolayer permeability. In contrast, 9- and 15-h modified release formulations showed marked reductions in Cmax (47.1 and 68.9%) and AUC0–72 (32.6 and 54.0%). Colonic intubation resulted in 81.3 and 73.8% reductions in Cmax and AUC0–72. Mechanistic studies in isolated mouse tissues showed that colonic UK-338,003 permeability (Papp < 0.5 × 10-6 cm/s) was at least 40 times lower than that for ileum with marked asymmetry. UK-338,003 was found to be a substrate for P-glycoprotein (PGP) with a weaker interaction for multidrug resistance-associated protein-type transporters in mouse intestine. PGP inhibition dramatically increased colonic UK-338,003 permeability to the levels observed in ileum. Low UK-338,003 apical to basolateral permeability was also observed in ex vivo human distal intestine, but both the asymmetry and increase in permeability after PGP inhibition were significantly lower. In conclusion, the poor absorption of MR UK-338,003 in humans can be explained by a combination of PGP-dependent efflux and low intrinsic permeability in the lower bowel. Regional permeability studies in ex vivo tissues used during drug development can highlight absorption problems in the distal bowel and assess the feasibility of developing successful MR formulations.
- 1 December 2005
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 26 (5) , 386-393
Comparison of P-glycoprotein-mediated drug–digoxin interactions in Caco-2 with human and rodent intestine: Relevance to in vivo prediction
- 1 December 2005
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 26 (5) , 386-393
Comparison of P-glycoprotein-mediated drug–digoxin interactions in Caco-2 with human and rodent intestine: Relevance to in vivo prediction
- 1 August 2004
- Published by Elsevier in Biochemical Pharmacology
- Vol. 68 (4) , 783-790
Rapid induction of P-glycoprotein expression by high permeability compounds in colonic cells in vitro: a possible source of transporter mediated drug interactions?
- 1 August 2004
- Published by Elsevier in Biochemical Pharmacology
- Vol. 68 (4) , 783-790
Rapid induction of P-glycoprotein expression by high permeability compounds in colonic cells in vitro: a possible source of transporter mediated drug interactions?
- 1 May 2004
- Published by Springer Nature in Pharmaceutical Research
- Vol. 21 (5) , 819-826
Predicting P-Glycoprotein Effects on Oral Absorption: Correlation of Transport in Caco-2 with Drug Pharmacokinetics in Wild-Type and mdr1a(-/-) Mice in Vivo
Purpose. Cell-based permeability screens are widely used to identify drug-P-glycoprotein (PGP) interaction in vitro. However, their reliability in predicting the impact of PGP on human drug...
- 1 May 2004
- Published by Springer Nature in Pharmaceutical Research
- Vol. 21 (5) , 819-826
Predicting P-Glycoprotein Effects on Oral Absorption: Correlation of Transport in Caco-2 with Drug Pharmacokinetics in Wild-Type and mdr1a(-/-) Mice in Vivo
Purpose. Cell-based permeability screens are widely used to identify drug-P-glycoprotein (PGP) interaction in vitro. However, their reliability in predicting the impact of PGP on human drug...